Related to NTRC Forges Drug Discovery Services Partnership with Carna

• Altor Scores $3M NCI Grant for Clinical Development of IL-2 Boosting Drug
  
• Roche Sequence Capture and Genome Sequencing Technologies to Be Evaluated for Cancer Genetics
  
• Sanofi-Aventis Gains License to Phase I Anticancer Agent from Merrimack for $60M Up Front
  
• Arginetix Pockets $10.75M to Further R&D of Arginase Inhibitors
  
• Scientists Find Major Role for GSK-3 Gene in Embryonic Brain Development
  
• FDA Awards Biosearch $3.4M for Surveillance Methods to Be Used in Pathogen Detection
  
• Researchers Link Anticancer Activity of Actinomycin D with NEDDylation Inhibition
  
• YM BioSciences to Take Over Cytopia Gaining Base in Australia
  
• Spirogen Receives About $24M for Clinical-Stage Anticancer Drug and Reacquires Development Rights
  
• Transgenomic Licenses Cold-PCR Technology from the Dana-Farber Cancer Institute
  
• TargetEx Takes Over Coordinating European CancerGrid Project
  
• Galapagos and Merck & Co. Expand Existing Metabolic Disease Alliance to Cover Atherosclerosis
  
• Serametrix Allies with Ludwig Institute to Exploit Tumor Antigens as Biomarkers
  
• BioTime Sets Up Subsidiary to Develop hESC-Based Therapies for Cancer
  
• Broad Institute to Use Genedata’s Small Molecule Screener
  
• Heptares Chooses Sygnature Chemical Services for Drug Discovery Contract
  
• Bayer Decides to Investigate Compugen’s Newly Discover Cancer Targets
  
• Genentech Taps Graffinity’s Fragment-Based Drug Discovery Technology
  
• Sangretech Gives Bostwick Scientific Rights to Its Dendritic-Cell Technology
  
• Fluofarma Teams Up with Roche to Develop Hepatotoxicity Tools